Exciting news for personalized mRNA cancer vaccines, especially if the phase 3 effect size matches the phase 2 trial (49% reduced death or recurrence), although we have to wait for the official numbers arstechnica.com/health/2026/...
mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say
The vaccine reportedly thwarted the cancer's return and spread.
arstechnica.com